Investigational drug · Phase 2
Lacutoclax
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL).
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Lacutoclax"
First trial start
2026
Jul 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lacutoclax", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma ( FL)
- Waldenström Macroglobulinemia (WM)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Lacutoclax" as an intervention, largest first.
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07609862 · 92 participants (planned) · Start Jul 14, 2026 · Primary completion Jun 30, 2029
Drug: Lacutoclax+Rocbrutinib · For: Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma ( FL) and 2 more
Sites: Tianjin, China
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07609823 · 75 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 30, 2028
Drug: Lacutoclax · For: Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.